Core Insights - Gossamer Bio, Inc. is under investigation by Levi & Korsinsky for potential violations of federal securities laws [1] Group 1: Company Overview - Gossamer Bio's lead pipeline candidate, Seralutinib, was evaluated in the PROSERA study, a pivotal Phase 3 trial for pulmonary arterial hypertension [2] - The PROSERA patient population was characterized by the company as well-suited to demonstrate a treatment effect [2] Group 2: Trial Results - During the Q1 2025 earnings call, CEO Faheem Hasnain expressed optimism about the trial results, stating that baseline characteristics were "precisely what we have targeted" and that the company had "over 90% power given the sample size" [3] - Despite reaching the planned enrollment target, the primary efficacy endpoint of the trial did not achieve the prespecified level of statistical significance [3]

Core Viewpoint - The law firm Kirby McInerney LLP is investigating Arq, Inc. for potential violations of federal securities laws or unlawful business practices by the company or its senior management [1]. Group 1: Company Actions - On March 9, 2026, Arq announced a decision to pause GAC production to conduct a comprehensive review of its engineering and production processes, resulting in no expected GAC production for fiscal year 2026 [3]. - Following this announcement, Arq's share price fell by $1.56, or approximately 48.8%, from $3.20 on March 9, 2026, to close at $1.64 on March 10, 2026 [3]. Group 2: Investigation Details - Currently, no lawsuit has been filed against Arq, but the investigation is ongoing to assess whether claims can be made under federal securities laws [4]. - Investors who purchased or acquired Arq securities and have information related to the investigation are encouraged to contact Kirby McInerney LLP for further discussion [4].

Core Viewpoint - Tennant Company experienced a significant decline in stock price due to issues with its new ERP system, leading to an investigation into potential violations of federal securities laws [1][6]. Group 1: Financial Performance - Tennant's GAAP net income for 2025 was reported at $43.8 million, representing a year-over-year decrease of approximately 47% [4]. - In Q4 2025, the company reported a net loss that was 166% lower than the net income from the same period the previous year [4]. - The financial impact of the ERP issues was quantified by management, estimating a $30 million loss in net sales due to operational disruptions [5]. Group 2: ERP System Issues - The North America ERP system went live in early November 2025, introducing severe functionality issues that hindered order entry, product shipping, and customer service [5]. - Management indicated that the challenges faced in Q4 2025 would extend into early 2026, affecting overall operations [5]. Group 3: Market Reaction and Investigation - Following the announcement of the ERP issues, Tennant's market capitalization decreased by approximately $343 million [6]. - Hagens Berman is investigating the timeline of when Tennant became aware of the ERP problems and whether any critical information was concealed from investors [6].

Core Viewpoint - Corcept Therapeutics Incorporated is under investigation for potential violations of federal securities laws following the FDA's denial of approval for its new drug application for relacorilant, leading to a significant drop in its stock price [1][2][3]. Group 1: Company Developments - On December 31, 2025, Corcept announced it received a Complete Response Letter (CRL) from the FDA, denying approval for relacorilant as a treatment for hypertension secondary to hypercortisolism [2]. - The FDA acknowledged previous trial results but required additional evidence of effectiveness for a favorable benefit-risk assessment [2]. Group 2: Market Reaction - Following the FDA's announcement, Corcept's stock price fell by $31.42, a decrease of 44.76%, opening at $38.78 per share, marking a new 52-week low [3]. - This stock price drop reflects levels not seen since September 2024, indicating a significant market reaction to the FDA's decision [3].

Core Viewpoint - Johnson Fistel, PLLP has initiated an investigation into Live Nation Entertainment, Inc. for potential breaches of fiduciary duties and violations of federal securities laws [1] Group 1: Investigation Details - The investigation follows a class action complaint alleging that Live Nation made materially false and misleading statements and failed to disclose adverse facts about its business and operations [2] - Specific allegations include that Live Nation engaged in anticompetitive conduct, such as charging high fees and retaliating against venues, which could lead to regulatory scrutiny and reputational harm [2] Group 2: Shareholder Rights - Current stockholders who held Live Nation stock before February 23, 2022, are encouraged to contact Johnson Fistel to discuss their legal rights regarding the investigation [3]

Core Viewpoint - The Schall Law Firm is investigating Hims & Hers Health, Inc. for potential violations of securities laws following a significant drop in share price due to allegations of illegal practices and misleading marketing [1][2]. Group 1: Investigation Details - The investigation centers on whether Hims & Hers made false or misleading statements and failed to disclose critical information to investors [2]. - Novo Nordisk announced the termination of its relationship with Hims & Hers due to concerns over illegal mass compounding and deceptive marketing practices [2]. - Following the announcement from Novo Nordisk, Hims & Hers shares plummeted by over 32.4% in afternoon trading [2]. Group 2: Company Background - Hims & Hers Health, Inc. is involved in telehealth services and has faced scrutiny regarding its compliance with laws governing the sale of compounded drugs [2]. - The FDA has resolved a shortage of Wegovy® and confirmed that Novo Nordisk is meeting the demand, which has implications for Hims & Hers' business practices [2].